Adoptive T cell therapy: Addressing challenges in cancer immunotherapy - Test2 - elhamkhani - TriplyDB

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

http://www.wikidata.org/entity/Q24805804

about

From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.Autologous tumor rejection in humans: trimming the myths.Profound impairment of adaptive immune responses by alkylating chemotherapy Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Immunotherapy for the treatment of breast cancer.Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells.Expansion and Antitumor Cytotoxicity of T-Cells Are Augmented by Substrate-Bound CCL21 and Intercellular Adhesion Molecule 1.

P2860

Q26865532-D2F31095-8F54-46B4-AA12-19905F06524A Q34111789-E7F4A68B-80D8-43F3-903C-1A694F61C917 Q35012607-AC66B0D8-FB7B-46E0-A421-204156D985F2 Q35634680-1AF8CFDE-8647-4ABF-86BC-C4115BC54321 Q35828752-4A797E1C-9D82-4B24-913B-23D563A7DFDD Q36569014-9446E24C-5F5C-46A5-B2A9-19DDE2A1E053 Q36922577-D0948068-1D04-44B7-A24B-C2B7126FCCF7 Q37582184-796F9BC4-64DB-493E-8170-BD8B085E3870 Q37729146-02D49F0F-E669-4E2F-9D6B-9E72ACEE56A7 Q38245925-73C6AF1D-72D3-4983-9031-8CB99F7DE0CA Q38353772-AD986404-9B86-4F13-877B-D182ED191348 Q38435415-C53B6CBF-2369-492D-BEAA-28C6A9847D0D Q39374243-FC2A4B13-181F-4D10-A38B-88D65EFFDD88 Q55446962-2ACDD5B2-9687-45F4-922D-E945C364E5BF

P2860

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

http://www.wikidata.org/entity/Q24805804

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@ast

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@en

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@nl

type

label

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@ast

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@en

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@nl

prefLabel

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@ast

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@en

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@nl

P1433

Q24805804-8D245077-B2DA-469D-8BA4-F50D2B78EDC9

P1476

Q24805804-ECC84629-932C-40CC-9AE0-F4A0117FB000

P2093

Q24805804-229DEEB5-09D2-4B2E-ADE2-FBC911425EAD

P2860

Q24805804-06304FBE-D945-4513-A3ED-397FB0ECEEE1

Q24805804-073BEBD8-C2C9-41CE-9E3F-57761D714010

Q24805804-08AB2067-BC12-49C1-A615-3B736058DB43

Q24805804-0AD17236-47BB-4D02-A9B8-A704330C1904

Q24805804-138CD6CC-19F5-4B77-92FC-A14507092704

Q24805804-142C69E8-CB70-400C-8512-C689812E766E

Q24805804-14AFE183-80F8-4055-9980-D1EBB77AE245

Q24805804-1BE9AEA4-037B-4792-9DCA-D8F30DA78EC5

Q24805804-2BBE7AFA-E3AD-4884-BE42-E50CD2A10984

Q24805804-2E283EC7-59F8-43EF-B7A3-88DB41794E44

P2888

Q24805804-ED7827DC-9435-4DF1-A65C-0D1249B45D46

P304

Q24805804-80F95C05-7DCB-4815-A656-3344F7C9B2C0

P31

Q24805804-0F4BAF14-B80D-45D4-93B9-1662151756EF

P356

Q24805804-7E4551CC-68CA-495B-A69E-399AE2422DF3

P433

Q24805804-029479CB-B530-4E6C-993D-CD50E5BFFC62

P478

Q24805804-EF528072-0F4D-449E-98A1-4959C0344C1A

P577

Q24805804-FB63E185-DFF3-47E7-AA46-9906DA31CE61

P5875

Q24805804-860D674E-F64F-4239-841E-8DB67769A720

P6179

Q24805804-7FF4A242-7415-4F02-9565-0588A59FD49A

P698

Q24805804-EC1F2F4B-25E8-44A6-839B-7507ACE87498

P921

Q24805804-57BBD694-4271-4884-8641-33A1F6576B59

P932

Q24805804-483341C9-4C70-4F34-948B-21F0C9E3F6B2

P356

P1433

Journal of Translational Medicine

P1476

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

@en

P2093

Cassian Yee

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Diversity and recognition efficiency of T cell responses to cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

TCRs with high affinity for foreign pMHC show self-reactivity.

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

P2888

P304

17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-3-17

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7878238

http://www.w3.org/2001/XMLSchema#string

P6179

1050371002

http://www.w3.org/2001/XMLSchema#string

P698

15860133

http://www.w3.org/2001/XMLSchema#string

P921

P932

1131930

http://www.w3.org/2001/XMLSchema#string